Loading...
Loading...
SYBX| Name | Value |
|---|---|
| Revenues | 0.2M |
| Cost of Revenue | 1.4M |
| Gross Profit | -1.2M |
| Operating Expense | 16.4M |
| Operating I/L | -16.2M |
| Other Income/Expense | 0.6M |
| Interest Income | 0.6M |
| Pretax | -15.6M |
| Income Tax Expense | -0.6M |
| Net Income/Loss | -15.0M |
Synlogic, Inc. is a clinical-stage biopharmaceutical company focused on developing synthetic biotic medicines for metabolic and immunological diseases. The company's product pipeline includes orally administered, non-systemically absorbed drug candidates such as SYNB1618 and SYNB1934, currently in Phase II clinical trials for phenylketonuria treatment, and SYNB1353 for homocystinuria. Additionally, SYNB8802 is in Phase I clinical trial for enteric hyperoxaluria. Synlogic is also developing SYNB1891, an intratumorally administered synthetic biotic medicine for solid tumors and lymphoma. The company generates revenue through collaborations with F. Hoffmann-La Roche Ltd, Hoffmann-La Roche Inc., and Ginkgo Bioworks, Inc.
